Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408518 | 1.00 | DRD2 (0.36) | DRD2DRD3KAT2BKDM2B | |
| SCHEMBL17189766 | 1.00 | DRD2 (0.36) | DRD2DRD3KAT2BKDM2B | |
| SCHEMBL840274 | 0.93 | KAT2B (0.33) | DRD2DRD3KAT2B | |
| SCHEMBL14199815 | 0.86 | — | — | |
| SCHEMBL408517 | 0.86 | — | — | |
| SCHEMBL14769610 | 0.86 | — | — | |
| SCHEMBL840364 | 0.86 | HRH3 (0.34) | DRD2DRD3KAT2B | |
| SCHEMBL20243619 | 0.84 | KAT2B (0.30) | DRD2DRD3KAT2B | |
| SCHEMBL29323288 | 0.83 | OPRM1 (0.31) | — | |
| SCHEMBL23103570 | 0.83 | DRD2 (0.35) | DRD2DRD3KAT2BKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 638 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| EP-3749355-B1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIV MIAMI (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-3846793-B1 | EIF4E INHIBITORS AND USES THEREOF | PIC THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7250413-B2 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | DRD2 608/4885DRD3 432/4885KAT2B 1598/4885 |
| US-20070238694-A1 | Purine compounds and methods of use thereof | PNP, ADORA2A, P2RY1 | DRD2 3085/4885DRD3 3929/4885KAT2B 4765/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | DRD2 4447/4885DRD3 4209/4885KAT2B 385/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | DRD2 4265/4885DRD3 4022/4885KAT2B 384/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | DRD2 4858/4885DRD3 4738/4885KAT2B 1117/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | DRD2 4598/4885DRD3 4410/4885KAT2B 1108/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | DRD2 2642/4885DRD3 2399/4885KAT2B 1055/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | DRD2 4836/4885DRD3 4831/4885KAT2B 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.